The KRAS mutation follows the loss of PTEN (phosphatase and tensin homolog), a tumor suppressor that inhibits the activation of the PI3K/Akt pathway, which is hyperactivated in 60% of pancreatic cancer cases (10, 12–14). This evidence concerns the gene KRAS and familial pancreatic carcinoma.